Allain H, Reymann J M, Bentue-Ferrer D, Pape D, van den Driessche J, Sabouraud O
Psychopharmacology (Berl). 1980;70(3):313-5. doi: 10.1007/BF00427893.
A single oral intake of 10 mg of Bromocriptine can modify both plasma renin activity (PRA) and arterial blood pressure (BP). The changes in both variables depend on the integrity of the central dopaminergic systems. The parkinsonians whose extrapyramidal symptoms are markedly improved by L-Dopa in association with a decarboxylase inhibitor (IDC) and the untreated parkinsonians are the only patients whose PRA and BP are lowered 1 h after Bromocriptine ingestion. The results obtained in the L-dopa-induced dyskinetic parkinsonians are similar to those obtained in the group of L-Dopa-resistant patients. This points to the paradoxical hypothesis of dopaminergic hyposensitivity in the dyskinetic patients. In spite of the absence of correlation between PRA and BP, it is possible that lowering of BP by Bromocriptine is linked to the parallel decrease of PRA. An increase of the BP may be obtained in the dyskinetic and L-Dopa-resistant groups. These data point to a possible involvement of central dopaminergic systems in some aspects of hypertension.
单次口服10毫克溴隐亭可改变血浆肾素活性（PRA）和动脉血压（BP）。这两个变量的变化取决于中枢多巴胺能系统的完整性。服用左旋多巴（L-Dopa）联合脱羧酶抑制剂（IDC）后锥体外系症状明显改善的帕金森病患者以及未经治疗的帕金森病患者是仅有的在摄入溴隐亭1小时后PRA和BP降低的患者。在左旋多巴诱发运动障碍的帕金森病患者中获得的结果与在左旋多巴抵抗患者组中获得的结果相似。这指向了运动障碍患者多巴胺能低敏的矛盾假说。尽管PRA和BP之间不存在相关性，但溴隐亭降低血压可能与PRA的平行降低有关。在运动障碍和左旋多巴抵抗组中可能会出现血压升高。这些数据表明中枢多巴胺能系统可能在高血压的某些方面发挥作用。
